Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Getinge, Audiocast, Q1'25

By Inderes4/22/2025, 11:00 AM
Getinge

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Mattias Perjos
00:00 - 05:15

Thank you very much. Welcome, everyone, to today's conference. Uh, today we'll first focus on a quick look into our performance in the first quarter and then reflect a bit on the current market situation and our expectations for 2025. So we can jump directly to page number two, please. Looking then at some of the key takeaways when it comes to the performance from the first quarter. Uh, we do look back at a solid quarter when it comes to the top line. Uh, our order intake grew by 7.1%. Uh, and, uh, it was 2.9% organic growth out of this. Our net sales increased by 10.7% in the quarter, where organic growth was 6.2%. The positive development was primarily attributed to Acute Care Therapies and, from a geographic perspective, to the Americas. When it comes to the adjusted gross and EBITA margins, they improved by about one percentage point in the quarter, and this was mainly thanks to leverage from volume acquisitions. Healthy price increases and positive product mix contributed to this as well. Currency was a headwind and weighed on the EBITA margin in the quarter. When you look at our financial leverage, it's now back at a similar level to last year, despite the increased net debt level following the acquisition of Paragonix. So that means our financial position remains solid. We can then move to page number three, please. So I just wanted to touch briefly on some of the key activities and events during the first quarter of this year. Let's start with sustainability and quality. So securing compliant quality in our products and operations continues to be our highest priority. I'm happy now to see that the KPIs supporting these efforts are trending positively. We can see, for example, that both findings per regulatory audit and field corrections in relation to net sales are continuing to go down year on year. We also observe a positive downward trend for our CO2 footprint in Scope 1 and 2, thanks to an increased share of renewable electricity and gas. When it comes to the offering and our customers. So if we start with Paragonix, they continue their healthy growth journey since the acquisition last year. The latest product launch, the KidneyVault, is designed to protect the most in-demand organ during transportation and has been a success with positive user feedback. Furthermore, we now have EU MDR approval for the large majority of products, which is an important milestone in the expansion outside of the US, an initiative that we're kicking off this year. The intended phase-out of the product category Surgical Perfusion is following our plan. It impacts organic order intake and net sales negatively, but it's still expected to be accretive to margins already now in 2025. In Life Science, we launched our DPT Flex Alpha port, which is an important addition to our Sterile Transfer portfolio and an important part in serving our pharma customers in this important segment. We can then move over to page number four and our top line performance. Overall. As I said, there is good top line momentum, particularly with strong performance in Acute Care Therapies and in the Americas region. Our order intake grew 7.1% in the quarter, whereof 2.9% was organic growth. Acute Care Therapies grew high single digits, coming mainly from ventilators in critical care and ECLS disposables within our Cardiopulmonary product category. In spite of double-digit growth in Sterile Transfer, Life Science was significantly down when it comes to order intake, and this is mainly due to weak orders in the Bio-Processing subsegment. Surgical Workflows grew orders slightly thanks to continued strong performance in Infection Control. When it comes to sales, we grew 10.7% in the quarter, whereof 6.2% was organic growth. Acute Care Therapies delivered double-digit organic growth coming from the same categories as orders. Uh, so ventilators and disposables again. Besides Bio-Processing, where the market globally has been challenging for some time now, mitigating actions are ongoing to both reignite sales and also right-size costs, specifically when it comes to our Bio-Processing structure. Surgical Workflows was basically flat year on year. All in all, when zooming in, infection control consumables grew by almost 10%, while sales were soft in digital health solutions and in surgical workplaces. With that, we can move over to page number five, and I'll hand over to you briefly.

Agneta Palmér
05:16 - 08:13

Thank you, Mattias Perjos. So once again, we see a positive impact from the leverage that we get on margins when sales volumes increase and restructuring efforts come into effect. Adjusted gross profit increased by about half a billion SEK to 4,337,000,000 SEK in the quarter, primarily due to volume acquisitions, continued price increases, and a favorable mix. Gross margin was up by 0.8 percentage points in total, thanks to a positive contribution from Acute Care Therapies to the adjusted EBITDA margin. The positive effect from adjusted gross profit contributed 0.3 percentage points, excluding currency effects. Thanks to those factors that I just mentioned, I'm pleased to see that we continue with a good trend on OpEx, which had a 1.5 percentage point positive impact on the margin in the quarter when adjusting for currency. And this was mainly due to operating leverage effects which had a negative impact on the margin in the quarter by 1.1 percentage point. So all in all, this resulted in an adjusted EBITDA of 1,003,000,000 SEK, improving our margin by about one percentage point year on year to 12.1%. Let's then move to page 60. Free cash flow decreased in the quarter to 0.2 billion SEK compared with last year. Free cash flow was impacted by volume-driven inventory increases, lower operating liabilities, and some payments from last year's restructuring activities. There was also some unfavorable timing of accounts receivables compared to the prior year. At the end of Q1. Net debt amounted to 9.7 billion SEK. If we adjust for pension liabilities, we are at 7.3 billion SEK. So this brings us to a leverage of 1.4 times adjusted EBITA, which is well below the 2.5 times we have as an internal threshold. If we adjust for pension liabilities, leverage is at 1.1 times adjusted EBITDA. This signals that we remain in a solid financial position, and we are actually at the same leverage as last year, even though we have made investments in strategic acquisitions which have amounted to approximately 4.2 billion SEK. By the end of the quarter. So all in all, we can conclude that the financial position continues to be strong. Let's then move, please, to page seven and back to you. Mattias.

Mattias Perjos
08:14 - 14:50

So this signals that we remain in a solid financial position, and we are actually at the same leverage as last year, even though we have made investments in strategic acquisitions since then, which has amounted to approximately 4.2 billion SEK. Thanks, Agneta. When it comes to our strategy for profitable growth, there are some key enablers that we focus on. And part of this is about increasing the share from recurring revenue. Accelerating the share of sales from high-margin products like ECLS and also Beta Bags in our Sterile Transfer product category. And this all should be supported by solid and effective quality processes. So these improvements should, of course, be achieved through responsible leverage and an attractive long-term return on invested capital. We clearly see that we're delivering according to our plan in this respect, as all those KPIs are trending in the right direction. You can see that sales from recurring revenue are now at 65%, and the high-margin products currently make up about two-thirds of our sales. When it comes to quality, the number of field actions in relation to sales has also decreased significantly, which is a positive leading indicator for the hard work that's been ongoing for quite some time. With this, we can move over to page eight, please. So in addition to our quarterly performance, I wanted to spend some time talking about what's going on in the world right now and how we navigate this. There's certainly a lot of dynamics in the market related to the geopolitical uncertainty that we're seeing now. So here are three examples of areas offering both some challenges and opportunities for us when it comes to tariffs. The current situation with increased trade barriers and higher tariffs is, we believe, unfortunate. We're a global company with a global footprint, which naturally mitigates this to some extent. And I'll touch on that a little bit more in the coming slides here. When it comes to budgets, there is a trend for more investment in defense and the civil sector, where we also hope to be able to contribute. Germany's plan is valued at €500 billion. Plan is, uh, one concrete example of this. Furthermore, the ambition of the healthcare sector to become more productive aligns well with the strength of our products and service portfolio. And then specifically in the US, we have lately seen some pause in research funding impacting our life science sales to customers within this business area. On the other hand, we do note as well that several big pharma companies are preparing for US expansion, and that's something that we are well positioned to support them with. Uh, when it comes to some of the structural changes at the FDA that have been in the news, this has not yet resulted in any negative impact for us. We continue to have a constructive dialogue on a weekly basis. So the way we address these dynamics is, for example, by continuing to have a close dialogue with our customers and the authorities, who are stakeholders in our business. We will continue to make price adjustments if needed and where possible. So, this is ongoing work, something that we've been working on for many years. And that needs to be accelerated a bit now. And we will also be agile when it comes to the allocation of volumes to secure profitability throughout our operations. We can then move to page number nine and just wanted to share an overview of our global footprint. So we have, I would say, a geographically well-diversified production footprint. We have 25 production sites spread over nine countries. So on the slide here, you can see an overview of our footprint broken down by product category. So in the US and EU, we produce for all business areas. While the Chinese site in Suzhou supports Acute Care Therapies and Surgical Workflows. Let's then move to page number ten please. Um, and when it comes to our sales in the US, about 60% of everything that we sell in the US is also produced domestically. Uh, and you can see on the slide here an overview per macro region. So when translating this into sales, you get 60% of sales in the US produced in the US that I just mentioned. Still a lot of uncertainty and changing dynamics related to the tariff situation. So we will not comment on any potential financial impacts of this yet. But hopefully the view shared here should bring some clarity when it comes to our exposure. So with that, let's move to page 11 please. And the outlook for the year. So the outlook for 2025 is unchanged. Uh, we remain with our expectation for organic net sales growth to be in the range of 2 to 5% compared to last year's sales. And this outlook then assumes sales contribution from the intended phase-out of the Surgical Perfusion business at about two-thirds of the 2024 figures, which equates to roughly 300 million SEK. In addition, we expect recent acquisitions to contribute about 2% to growth this year. We can then move to page 12. Please. So just to summarize some of the key takeaways for the quarter, we've delivered a very strong performance when it comes to net sales. Uh, and uh, also with improved margins. Our leverage continues to decrease, now reaching the same level as before the acquisition of Paragonix. And our financial position overall remains very solid. We stand by our outlook for 2025, which will be a guide for organic net sales growth of 2 to 5%. Our priorities for 2025 remain unchanged. It's about addressing the remaining challenges in Acute Care Therapies when it comes to our quality. It's about sustainable productivity improvement and cost consciousness when navigating the geopolitical uncertainty that's been with us for a while now. And it's about continuing to create value for our customers. So with that summary, I open up for questions. We stand by our outlook for 2025, which will guide an organic net sales growth of 2 to 5%.

Operator
14:56 - 15:15

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Richard Andrew from Handelsbanken. Please go ahead.

Unknown 1
15:17 - 15:54

Good afternoon and thank you for taking my questions. So, two from my side, please. There's been quite an outstanding performance in the Americas for Acute Care Therapies. It would be interesting to hear a bit more on the background there. What visibility do you have around potential stocking both from a strong flu season and potential pre-buying ahead of tariffs here? You know, given the historical supply chain volatility around, for example, consumables, is it not reasonable to assume some customer interest in sort of stocking up in a more uncertain environment? We stand by our outlook for 2025; we will guide for organic net sales growth of 2 to 5%.

Mattias Perjos
15:56 - 16:57

Yes. Yes. We stand by our outlook for 2025 and will guide for organic net sales growth of 2 to 5%. I mean, the strong performance in the US for Acute Care Therapies is largely attributable to ventilators and to ECLS. When it comes to ventilators, we don't think this has anything to do with stocking. This is merely the next step in the shift towards the remaining suppliers of ventilators that we've observed since the end of last year. Really? That's really the main factor. So that's something that we believe is going on according to expectations and to our plans, and we're in a good position to support that. I think our team has done an outstanding job when it comes to delivering ventilators. Both at the end of last year, and during the first quarter of this year. When it comes to the ECLS consumables part, I think there is a flu effect in Q1, whether there's any stocking or kind of hoarding in this, I. We have no evidence of that at all. I can't rule it out, but we have nothing to support that.

Unknown 1
17:00 - 17:35

All right. That's very clear. Uh, second question, uh, on the margin in Surgical Workflows, uh, you know, with growth in the Americas and higher sales contribution from recurring revenues in this segment, uh, can you elaborate a little bit on the softer margin development, even excluding FX? Um, anything we should keep in mind there? And if you have thoughts on how we should think about the underlying margin trend going forward in Surgical Workflows, it just stood out a little bit as on the softer side compared to the sort of mix development.

Agneta Palmér
17:36 - 18:01

Yeah. Thank you for that question. I can say the short answer is that if we adjusted for currency, it is very much in line with last year, and we are continuing to see good development in infection control, consumables, and good growth there. We have, in this quarter, some adverse product mix on the capital side that impacts this margin. But the major effect that you're seeing is from currency.

Unknown 1
18:04 - 18:06

We have no evidence of that at all. I'll stop there. Thank you for taking my questions.

Operator
18:11 - 18:15

The next question comes from Mathias Madsen from SEB. Please go ahead.

Unknown 2
18:19 - 18:51

Hello. Good afternoon. I have two questions as well. So, starting off on ECMO, there seems to be strong demand here. Obviously once again in this quarter, as I understand it, Getinge is perhaps most critical to the sales development in terms of having stability in production. So my question is, do you expect this to be the case also for the coming quarters through 2025, or how should we look at the sales development in consumables going forward? That's the first one.

Mattias Perjos
18:52 - 19:27

Yeah. Yeah, I think you're right. Historically, we've been the bottleneck ourselves here, but we have added capacity. And, I think the team has done a really good job now for several months, with stable output and gradually working down the backlog situation that we've lived with for a while. So I think that we do expect that to continue. It is a more and more robust operation. And, uh, we, uh, certainly hope not to be the bottleneck going forward, so that you'll see the real end market demand reflected also in our order intake and sales.

Unknown 2
19:31 - 20:04

Thank you for that. And then in terms of margin in the Life Science segment, it was obviously very strong in Q4 and then weaker here in Q1. And it has been a volatile segment when it comes to margins. Do you think we will likely have to live with that, given the difference in margin among product segments? Or how should we look at the margin trajectory for Life Science? Is this around the bottom that we're at right now, or how do you see it? That's the second one.

Agneta Palmér
20:09 - 20:26

So regarding margin on Life Science, to your point, there is a volume effect that is very strong on the margin. So in Q4, when we had the strong volumes, we did get very good leverage from that. And then somewhat the opposite is true in the first quarter.

Unknown 2
20:29 - 20:57

Thank you. And then maybe squeeze in one more. Looking at the group EBITDA margin trajectory for the full year, I think on the last conference call, we discussed the slight margin uptick for 2025. So yeah, how are you communicating around margins for the full year now, in light of the uncertainties that you alluded to on Paris and the effects and other drivers? That's the last one. Thank you.

Mattias Perjos
20:57 - 21:38

I think the main point when it comes to margins is that we stand by the guidance that we gave at the Capital Markets Day. When it comes to the 16 to 19% EBITA margin span for 2028, regarding some of these short-term dynamics, it's impossible to say as it's too early. We need to understand that the message regarding tariffs has changed on a weekly basis. Uh, and there is a time lag in how one can pass on price increases. We need to work with some of the costs and some of the supply chain flows. And this as well. It's not possible to model those dynamics right now. So we can't answer anything in the short term.

Unknown 2
21:40 - 21:41

I appreciate that. Thank you very much.

Operator
21:47 - 21:51

The next question comes from Eric Castle from Danske Bank. Please go ahead.

Unknown 1
21:54 - 21:54

Hi.

Unknown 3
21:54 - 22:26

Um, first I want to ask about Life Science and especially Bio-Processing. I mean, they just released numbers and were quite upbeat about the Bio-Processing momentum in general. Um, and I think general comments have been quite positive from other peers as well. So I wanted to ask to what extent do you think this might be a Getinge-specific issue? And if you could provide some more details on the Life Science issues and how temporary they might be.

Mattias Perjos
22:27 - 23:29

Um, yeah. It's hard to say how temporary they are. If you look at, uh, some of the weakness in Life Science now, it is related to the NIH funding cuts. If you look at the, almost the entire reduction compared to last year when it comes to order intake, it can be explained by projects that have been put on hold. So that is definitely a factor for us. How specific to Getinge that is, I don't know. Uh, it's difficult to get anything from our peer report, I think so far at least. So that's something we'll have to continue to monitor then. I think when it comes to comparison with some of our peers as well, we, uh, historically we've had a relatively large presence in China and relatively large R&D exposure in our part of the portfolio. And there are some single customer dependencies that may be a bit more pronounced for us as well. So if I look at the broader customer base, we do have good momentum with quite a few of those customers as well. So it is, I think, somewhat of a Getinge-specific impact in the numbers for this quarter.

Unknown 3
23:33 - 23:58

Um, first I want to ask about Life Science and especially Bio-Processing. Um, first I want to ask about Life Science and especially Bio-Processing. Um, and then I realized, you know, Paragonix was doing well this quarter. Maybe stocking, maybe not. But is there any chance you can give comments on how the hardware side of it is doing and in terms of market share in new system sales and sort of how it's holding up?

Mattias Perjos
23:59 - 24:17

No, we can't dissect that any more than we've singled out some of the numbers that deviate quite a bit now, and this time it was the positive one when it comes to the consumables. But there isn't anything else that stands out that we can point out regarding hardware performance right now.

Unknown 3
24:20 - 24:37

Um, first I want to ask about Life Science and especially Bio-Processing. Um, first I want to ask about Life Science and especially Bio-Processing. And just the last question, I know you said that you don't really want to comment on margins, but just on the pure FX impact compared to last year where we stand at spot. Um, can you give us any indication of what you think a potential clean FX impact would be?

Mattias Perjos
24:38 - 24:39

You mean for the full year or?

Unknown 3
24:42 - 24:43

Yeah, for the full year.

Agneta Palmér
24:44 - 25:01

Yeah. So I will say this. We will not speculate on currency movements. In general terms, we are favored by a stronger US dollar. But the main effect that we're seeing in Q1 is this revaluation effect. So the fast movement downwards of the dollar.

Unknown 3
25:06 - 25:07

All right. Thank you.

Operator
25:13 - 25:17

The next question comes from Christopher Lilienberg from Carnegie. Please go ahead.

Unknown 4
25:20 - 25:48

Yeah. Thank you. Three questions. First, if you could just give an update on how the work is progressing for solving the quality issues. And then I want a little bit of information about the demand situation for Surgical Workflows. That seems to be more flat during the quarter. And finally, given the working capital buildup in the quarter, could you say anything about the outlook for working capital for the full year and how we should think about that? Thank you.

Mattias Perjos
25:50 - 26:56

Yeah. When it comes to quality, I think it's one of the areas that's been performing well for another quarter now, with steady progress on remediation work. I mentioned briefly in the call, a lot of the leading indicators are now pointing in the right direction when it comes to everything from medical device reporting to field actions, which are going well. So we're pleased with the progress when it comes to quality. When it comes to the Surgical Workflows demand. Uh, nothing particular to call out. Uh, you know already that it's a somewhat lumpy business by nature. Uh, but nothing else. Uh, we haven't noticed any, uh, real big constraints when it comes to CapEx spending. For example, uh, there's a little bit of wait and see in some areas, but that's probably more related to Life Science than to, uh, Surgical Workflows, I would say. And when it comes to the working capital build up. Like Agneta said earlier, it is a volume increase-related buildup of working capital. There are some timing effects in there as well. But we don't make any projections for the full year.

Unknown 4
27:02 - 27:03

Thank you.

Operator
27:09 - 27:15

The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.

Unknown 1
27:17 - 27:55

Thank you and good day, everyone. A question on the tariffs. I understand you're not willing to provide any financial impact of it. But could you at least provide us with how much of the US sales manufactured in the US is actually sourced from the US? Um, is that 100%, or are all US sales manufactured in US production facilities? Um, do you source from other countries? That would be helpful to understand.

Agneta Palmér
27:57 - 28:02

Yeah. Just in the US, it is also sourced within the US.

Unknown 1
28:04 - 28:10

So there are no components from other regions. That's good.

Agneta Palmér
28:11 - 28:16

There are some components. The absolute majority, I repeat, the majority of it is bought within the US.

Unknown 1
28:18 - 28:45

There are some timing effects in there as well. So when do you think you will know how this will impact you? Um, given what we know today, we obviously don't know if the tariffs will go away. Um, you know, tomorrow or next year, but based on what we know today. I think some kind of guidance would be very helpful.

Mattias Perjos
28:47 - 29:18

Yeah, but it's too early to say anything about this. As I said, there are still a lot of changes in how the tariffs are being decided. There is this 90-day grace period that we're in now with negotiations ongoing. There's still discussions about potential exemptions for certain product categories. And so, it is futile to try to forecast the impact of what this will be at this time. It's just too early. Even if we wanted to, there's no way we could do this in a good way today.

Unknown 1
29:20 - 29:23

So right now, today, you're not paying any tariffs?

Mattias Perjos
29:24 - 29:31

Yes, we are. Since the beginning of April, tariffs have also been implemented for medical devices.

Unknown 1
29:32 - 29:48

Okay. My final question is on mitigating factors here. Are you able to raise prices locally quickly? Or is that more of a lengthy process? Um.

Mattias Perjos
29:49 - 30:11

Yes, it is in our industry. We typically have rather long-term contracts. Uh, there are some mechanisms in place for adjusting prices and so on. But I think the most important thing is that there is a constructive dialogue with, uh, with customers regarding this. So that's something we're in the process of having right now, but it's way too early to discuss the outcome and the potential impact of this.

Unknown 1
30:13 - 30:16

Okay. Excellent. Thank you very much. That's it for me.

Mattias Perjos
30:16 - 30:17

Yes, we are.

Operator
30:21 - 30:25

The next question comes from Isaiah Noor from Morgan Stanley. Please go ahead.

Unknown 5
30:27 - 31:28

Hi. Good afternoon. Thanks for the question. I had one on the free cash flow, which is the weakest it's been this quarter in the past year. I know you mentioned some unfavorable movements in accounts receivables, but could you elaborate a bit more? The main contributing factors. Which divisions does this relate to? This relates to? And would you expect this weakness to persist throughout the remainder of 2025? My second question is on the Life Science business. Could you elaborate on the drivers of this 25% decline in the US, specifically between research funding, pharmaceuticals, etc.? Yes, we are. What are the main drivers of that decline? And then the third question is on tariffs, which is more impactful to you between European imports into the US or US imports into China? In terms of the magnitude of impact, what do you think it might have on you? And then beyond us, actually for those products where you think could be exempted from these tariffs, which divisions do you think could be exempted? Thank you.

Agneta Palmér
31:30 - 31:49

Okay. Thank you so much. If you start with the cash flow and the accounts receivable movements, this is a timing effect. So the answer is that we do not expect this to continue. It is related to the fact that we had a lot of deliveries very late in the quarter that are due for payments early in Q2.

Mattias Perjos
31:51 - 32:42

And when it comes to the Life Science part, almost the entire difference from last year's order intake is due to funding holds for some of our Life Science customers. And these are NIH funding holds specifically. Roughly half of those have already been released. Now we're at the beginning of April. However, speculating on the impact going forward is impossible. But the impact during Q1 and the beginning of April is what I explained here. Uh, and when it comes to tariffs, we cannot dissect that any more than what I showed slide-wise for you here, unfortunately. Uh, I think the key priority is to discuss whether there are any exceptions, particularly within Acute Care Therapies.

Unknown 5
32:44 - 32:45

Okay. Very helpful. Thank you.

Mattias Perjos
32:46 - 32:47

Thank you.

Operator
32:51 - 32:56

The next question comes from David Adlington from JP Morgan. Please go ahead.

Unknown 6
32:57 - 33:09

Hey everyone. Thanks for taking the question. Almost all my questions have been asked, but maybe just following up on the foreign exchange point if spot rates currently hold as they are. Could you quantify the impact on margins for this year, please?

Agneta Palmér
33:12 - 33:23

Sorry, David, we've had a bit of a bad reception. Your question, I repeat, was if currencies hold as they are now, how will we be impacted on the margin for the remainder of the year?

Unknown 1
33:23 - 33:23

Correct?

Agneta Palmér
33:23 - 33:24

Yes.

Unknown 6
33:24 - 33:24

Correct. Yeah.

Agneta Palmér
33:25 - 33:49

Slightly negative, but not to the extent that it has been negative in Q1, because the major negative effect is related to the movement and the revaluation of the receivables that we get from those movements. So if currencies hold from now, there will be a slight negative effect, but not from the revaluation effect then.

Unknown 6
33:51 - 33:52

Perfect. That's helpful. Thank you.

Operator
33:59 - 34:23

As a reminder, if you wish to ask a question, please dial the Pound Key followed by five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Mattias Perjos
34:25 - 34:37

Right. Thank you very much, everyone, for joining. We've already done the summary here, so I appreciate you taking the time to listen in today. And thank you for a very productive Q&A as well. So have a good rest of the day. Thank you very much.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…